Literature DB >> 15693640

The role of anticholinergics in chronic obstructive pulmonary disease.

Peter J Barnes1.   

Abstract

Anticholinergics are the bronchodilators of choice in the management of chronic obstructive pulmonary disease (COPD). They work by blocking muscarinic receptors in airway smooth muscle. Cholinergic tone appears to be the only reversible component of COPD. With the discovery of different muscarinic receptor subtypes, the development of more selective anticholinergics is possible. A major advance in this therapeutic area has been the discovery of tiotropium bromide, which has kinetic selectivity for M3 receptors as well as a duration of action of >24 hours. Once-daily administration of tiotropium is well tolerated and has shown significant advantages over ipratropium bromide, given 4 times daily, in the control of COPD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15693640     DOI: 10.1016/j.amjmed.2004.10.018

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  29 in total

1.  Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.

Authors:  Anthony Cahn; Rashmi Mehta; Andrew Preece; James Blowers; Alison Donald
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

2.  Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

Authors:  Shelley R Salpeter; Nicholas S Buckley; Edwin E Salpeter
Journal:  J Gen Intern Med       Date:  2006-10       Impact factor: 5.128

3.  Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways.

Authors:  Gino Villetti; Marco Bergamaschi; Franco Bassani; Pier Tonino Bolzoni; Selena Harrison; Paolo M Gigli; Alberto Janni; Pierangelo Geppetti; Maurizio Civelli; Riccardo Patacchini
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

4.  The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts.

Authors:  F Lamyel; M Warnken-Uhlich; W K Seemann; K Mohr; E Kostenis; A S Ahmedat; M Smit; R Gosens; H Meurs; A Miller-Larsson; Kurt Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-21       Impact factor: 3.000

Review 5.  Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy.

Authors:  Kesavan Suresh Babu; Jaymin Bhagwanji Morjaria
Journal:  Ther Adv Chronic Dis       Date:  2017-03-24       Impact factor: 5.091

6.  Muscarinic M3 receptors on structural cells regulate cigarette smoke-induced neutrophilic airway inflammation in mice.

Authors:  Loes E M Kistemaker; Ronald P van Os; Albertina Dethmers-Ausema; I Sophie T Bos; Machteld N Hylkema; Maarten van den Berge; Pieter S Hiemstra; Jürgen Wess; Herman Meurs; Huib A M Kerstjens; Reinoud Gosens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-07       Impact factor: 5.464

Review 7.  Pulmonary fibroblasts, an emerging target for anti-obstructive drugs.

Authors:  Kurt Racké; Susanne Haag; Amit Bahulayan; Mareille Warnken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-13       Impact factor: 3.000

8.  Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects.

Authors:  D Singh; R Tal-Singer; I Faiferman; S Lasenby; A Henderson; D Wessels; A Goosen; N Dallow; R Vessey; M Goldman
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

Review 9.  Novel long-acting bronchodilators for COPD and asthma.

Authors:  M Cazzola; M G Matera
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 10.  Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality.

Authors:  Shelley R Salpeter
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.